Orphan G-protein-coupled receptors: Strategies for identifying ligands and potential for use in eating disorders

Drugs in R and D

Volumn 8, Issue 5, 2007, Pages 287-299

  Harrold, Joanne A ^a   Halford, Jason C G ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHYL 6 BENZOXAZOLYL) 3 (1,5 NAPHTHYRIDIN 4 YL)UREA; ADENINE; AGOUTI PROTEIN; AGOUTI RELATED PROTEIN; CORTICOTROPIN RELEASING FACTOR; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GHRELIN; GROWTH HORMONE; HISTAMINE H4 RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; LIGAND; MELANIN CONCENTRATING HORMONE; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; NEUROPEPTIDE; NEUROPEPTIDE B; NEUROPEPTIDE W; NEUROPEPTIDE Y; NEUROPEPTIDE Y1 RECEPTOR; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; OREXIN A; OREXIN B; PROOPIOMELANOCORTIN; PROTEIN C FOS; SEROTONIN; SNAP 7941; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DIPHOSPHATE GLUCOSE;

DRUG RECEPTOR BINDING; DRUG SCREENING; EATING DISORDER; FEEDING BEHAVIOR; HUMAN; LIGAND BINDING; NEUROCHEMISTRY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

ANIMALS; ANTI-OBESITY AGENTS; EATING DISORDERS; HUMANS; LIGANDS; OBESITY; RECEPTORS, G-PROTEIN-COUPLED;

EID: 34548653259     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708050-00003     Document Type: Review

References (115)

1. Grucza RA, Przybeck TR, Cloninger CR. Prevalence and correlates of binge eating disorder in a community sample. Compr Psychiatry 2007; 48: 124-31
2. Devlin MJ, Walsh BT, Guss JL, et al. Postprandial cholecystokinin release and gastric emptying in patients with bulimia nervosa. Am J Clin Nutr 1997; 65: 114-20
3. Halford JCG, Harrold JA, Boyland EJ, et al. Serotonergic drugs: effects on appetite expression and use for the treatment of obesity. Drugs 2007; 67: 27-55
4. Harrold JE, Halford JCG. The hypothalamus and obesity. Rec Pat CNS Drug Disc 2006; 1: 305-14
5. Brewerton TD. Toward a unified theory of serotonin dysregulation in eating and related disorders. Psychoneuroendocrinology 1995; 20: 561-90
6. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921
7. Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. Science 2001; 291: 1304-51
8. Drews J. Drug discovery: a historical perspective. Science 2000; 287: 1960-4
9. Im D-S. Orphan G protein-coupled receptors and beyond. Jpn J Pharmacol 2002; 90: 101-6
10. Lin SH, Civelli O. Orphan protein-coupled receptors: targets for new therapeutic interventions. Ann Med 2004; 36: 201-14
11. Wise A, Jupe SE, Rees S. The identification of ligands at orphan G-protein coupled receptors. Ann Rev Pharmacol Toxicol 2004; 44: 43-66
12. Civelli O, Saito Y, Wang Z, et al. Orphan GPCRs and their ligands. Pharmacol Ther 2006; 110: 525-32
13. Chambers J, Ames RS, Bergsma D, et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 1999; 400: 261-5
14. Kojima M, Hosoda H, Matsuo H, et al. Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 2001; 12: 118-22
15. De Lecea L, Kilduff TS, Peyron C, et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95: 322-7
16. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behaviour. Cell 1998; 92: 573-85
17. Fujii R, Yoshida H, Fukusumi S, et al. Identification of a neuropeptide modified with bromine as an endogenous ligand for GPR7. J Biol Chem 2002; 277: 34010-6
18. Shimomura Y, Harada M, Goto M, et al. Identification of neuropeptide W as the endogenous ligand for orphan G-protein-coupled receptors GPR7 and GPR8. J Biol Chem 2002; 277: 35826-32
19. Brezillon S, Lannoy V, Franssen JD, et al. Identification of natural ligands for the orphan G protein-coupled receptors GPR7 and GPR8. J Biol Chem 2003; 278: 776-83
20. Libert F, Vassart G, Parmentier M. Current development in G protein-coupled receptors. Curr Opin Cell Biol 1991; 8: 218-23
21. Civelli O. Functional genomics: the search for novel neurotransmitters and neuropeptides. FEBS Lett 1998; 430: 55-8
22. Larhammer D, Blomqvist AG, Yee F, et al. Cloning and functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J Biol Chem 1992; 267: 10935-8
23. Wise A, Foord SM, Fraser NJ, et al. Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 2003; 278: 9869-74
24. Zhu Y, Michalovich D, Wu HL, et al. Cloning, expression, and pharmacological characterization of a novel human histamine receptor. Mol Pharmacol 2001; 59: 434-41
25. Fargin A, Raymond JR, Lohse MJ, et al. The genomic clone G-21 which resembles a beta-adrenergic receptor sequence encodes the 5-HT1A receptor. Nature 1988; 335: 358-60
26. Bunzow JR, Van Tol HH, Grandy DK, et al. Cloning and expression of a rat D2 dopamine receptor cDNA. Nature 1988; 336: 783-7
27. Civelli O. GPCR deorphanizations: the novel, the known and the unexpected neurotransmitters. Trends Pharmacol Sci 2005; 26: 15-9
28. Chambers JK, Macdonald LE, Sarau HM, et al. A G protein-coupled receptor for UDP-glucose. J Biol Chem 2000; 275: 10767-71
29. Bender E, Buist A, Jurzak M, et al. Characterization of an orphan G protein-coupled receptor localized in the dorsal root ganglia reveals adenine as a signalling molecule. Proc Natl Acad Sci U S A 2002; 99: 8573-8
30. Civelli O, Nothacker HP, Saito Y, et al. Novel neurotransmitters as natural ligands of orphan G-protein-coupled receptors Trends Neurosci 2001; 24: 230-7
31. Reinscheid RK, Nothacker HP, Bourson A, et al. Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor. Science 1995; 279: 792-4
32. Naito N, Kawazoe I, Nakai Y, et al. Melanin-concentrating hormone-like immunoreactive material in the rat hypothalamus; characterization and subcellular localization. Cell Tissue Res 1988; 253: 291-5
33. Skofitsch G, Jacobowitz DM, Zamir N. Immunohistochemical localization of melanin-concentrating hormone-like peptide in the rat brain. Brain Res Bull 1985; 15: 635-49
34. Tan CP, Sano H, Iwaasa H, et al. Melanin-concentrating hormone receptor subtypes 1 and 2: species-specific gene expression. Genomics 2002; 79: 785-92
35. Hervieu GJ, Cluderay JE, Harrison D, et al. The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, slc-1, in the central nervous system of the rat. Eur J Neurosci 2000; 12: 1191-216
36. Tsukamura H, Thompson RC, Tsukahara S, et al. Intracerebroventricular administration of melanin-concentrating hormone suppresses pulsatile luteinising hormone release in the female rat. J Neuroendocrinol 2000; 12: 529-34
37. An S, Cutler G, Zhao JJ, et al. Identification and characterization of a melanin-concentrating hormone receptor. Proc Natl Acad Sci U S A 2001; 98: 7576-81
38. Saito Y, Cheng M, Leslie FM, et al. Expression of the melanin-concentrating hormone (MCH) receptor mRNA in the rat brain. J Comp Neurol 2001; 435: 26-40
39. Rodriguez M, Beauverger P, Naime I, et al. Cloning and molecular characterization of the novel human melanin-concentrating hormone receptor MCH2. Mol Pharmacol 2001; 60: 632-9
40. Qu D, Ludwig DS, Gammeltoft S, et al. A role for melanin-concentrating hormone in the central regulation of feeding behaviour. Nature 1996; 380: 243-7
41. Shearman LP, Camacho RE, Sloan Stribling D, et al. Chronic MCH receptor modulation alters appetite, body weight and adiposity in rats. Eur J Pharmacol 2003; 475: 37-47
42. Chen Y, Hu C, Hsu CK, et al. Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology 2002; 143: 2469-77
43. Rossi M, Choi SJ, O'Shea D, et al. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 1997; 138: 351-5
44. Ludwig DS, Tritos NA, Mastaitis JW, et al. Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J Clin Invest 2001; 107: 379-86
45. Shimada M, Tritos NA, Lowell BB, et al. Mice lacking melanin- concentrating hormone are hypophagic and lean. Nature 1998; 396: 670-3
46. Marsh DJ, Weingarth DT, Nove DE, et al. Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc Natl Acad Sci U S A 2002; 99: 3240-5
47. Segal-Lieberman G, Bradley RL, Kokkotou E, et al. Melanin-concentrating hormone is a critical mediator of the leptin-deficient phenotype. Proc Natl Acad Sci U S A 2003; 100: 10085-90
48. Takekawa S, Asami A, Ishihara Y, et al. T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur J Pharmacol 2002; 438: 129-35
49. Borowsky B, Durkin MM, Ogozalek K, et al. Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002; 8: 825-30
50. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-7
51. Bednarek MA, Feighner SD, Pong SS, et al. Structure-function studies on the new growth hormone-releasing peptide, ghrelin, minimal sequence of ghrelin necessary for activation of growth hormone secretagogue receptor 1a. J Med Chem 2000; 43: 4370-6
52. Matsumoto M, Kitajima Y, Iwanami T, et al. Structural similarity of ghrelin derivatives to peptidyl growth hormone secretagogues. Biochem Biophys Res Commun 2001; 284: 655-9
53. Hosoda H, Kojima M, Kangawa K. Ghrelin and the regulation of food intake and energy balance. Mol Interv 2002; 2: 494-503
54. Guan XM, Yu H, Palyha OC, et al. Distribution of mRNA encoding the growth hormone secretagogue receptor in brain and peripheral tissue. Mol Brain Res 1997; 48: 23-9
55. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409: 194-8
56. Hewson AK, Dickson SL. Systemic administration of ghrelin induces Fos and Egr-1 proteins in the hypothalamic arcuate nucleus of fasted and fed rats. J Neuroendocrinol 2000; 12: 1047-9
57. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endrocrinology 2000; 141: 4325-8
58. Wren AM, Small CJ, Abbott CR, et al. Ghrelin causes hyperphagia and obesity in rats. Diabetes 2001; 50: 2540-7
59. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature 2000; 407: 908-13
60. Shintani M, Ogawa Y, Ebihara K, et al. Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 2001; 50: 227-32
61. Shuto Y, Shibasaki T, Otagiri A, et al. Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 2002; 109: 1429-36
62. Sun Y, Ahmed S, Smith RG. Deletion of ghrelin impairs neither growth nor appetite. Mol Cell Biol 2003; 23: 7973-81
63. Wortley KE, Anderson KD, Garcia K, et al. Genetic deletion of ghrelin dose not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 2004; 101: 8227-32
64. Sun Y, Wang P, Zheng H, et al. Ghrelin stimulation of growth hormone release and appetite is mediated though the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A 2004; 101: 4679-84
65. Kamegai J, Tamura H, Shimizu T, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50: 2438-43
66. Chen HY, Trumbauer ME, Chen AS, et al. Orexigenic action of peripheral ghrelin is mediated by neuropeptide Y (NPY) and agouti-related protein (AgRP). Endocrinology 2004; 145: 2607-12
67. Wren AM, Seal LJ, Cohen MA, et al. Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001; 86: 5992-5
68. Cummings DE, Purnell JQ, Frayo RS, et al. A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 2001; 50: 1714-9
69. Ariyasu H, Takaya K, Tagami T, et al. Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-8
70. Pinkney J, Williams G. Ghrelin gets hungry. Lancet 2002; 359: 1360-1
71. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are reduced in human obesity. Nature 2001; 407: 908-13
72. Otto B, Cuntz U, Fruehauf E, et al. Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 2001; 145: 669-73
73. English PJ, Ghatei MA, Malik IA, et al. Food fails to suppress ghrelin levels in obese humans. J Clin Endocrinol Metab 2002; 87: 2984-7
74. DelParigi A, Tschop M, Heiman ML, et al. High circulating ghrelin: a potential cause for hyperphagia and obesity in Prader-Willi syndrome. J Clin Endocrinol Metab 2002; 87: 5461-4
75. Ukkola O, Ravussin E, Jacobson P, et al. Mutations in the preproghrelin/ghrelin gene associated with obesity in humans. J Clin Endocrinol Metab 2001; 86: 3996-9
76. Korbonits M, Gueorguiev M, O'Grady E, et al. A variation in the ghrelin gene increases weight and decreases insulin secretion in tall obese children. J Clin Endocrinol Metab 2002; 87: 4005-8
77. Wang HJ, Geller F, Dempfle A, et al. Ghrelin receptor gene: identification of several sequence variants in extremely obese children and adolescents, healthy normal-weight and underweight students and children with short normal stature. J Clin Endocrinol Metab 2004; 89: 157-62
78. Miraglia del Giudice E, Santoro N, Cirillo G, et al. Molecular screening of the ghrelin gene in Italian obese children: the Leu72Met variant is associated with an earlier onset of obesity. Int J Obese Relat Metab Disord 2004; 28: 447-50
79. Asakawa A, Inui A, Kaga TK, et al. Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut 2003; 52: 947-52
80. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomized, controlled clinical trial. Ann Intern Med 2000; 133: 111-22
81. Helmling S, Maasch C, Eulberg D, et al. Inhibition of ghrelin action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci U S A 2004; 101: 13174-9
82. Smith RG, Pong SS, Hickey G, et al. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog Horm Res 1996; 51: 261-85
83. Halem HA, Taylor JE, Dong JZ, et al. Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol 2004; 151: S71-5
84. Zhang JV, Ren PG, Avsian-Kretchmer O, et al. Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake. Science 2005; 310: 996-9
85. Lagaud GJ, Young A, Acena A, et al. Obestatin reduces food intake and suppresses body weight in rodents. Biochem Biophys Res Commun 2007; 357: 264-9
86. Chartrel N, Alvear-Perez R, Leprince J, et al. Comment on "Obestatin, a peptide encoded by the ghrelin gene, opposed ghrelin's effects on food intake". Science 2007; 315: 766
87. Trembaly F, Perreault M, Klaman TD, et al. Normal food intake and body weight in mice lacking the G protein-coupled receptor GPR39. Endocrinology 2007; 148: 501-6
88. Lauwers E, Landuyt B, Arckens L, et al. Obestatin does not activate orphan G protein-coupled receptor GPR39. Biochem Biophys Res Commun 2006; 351: 21-5
89. Seoane LM, Al-Massadi O, Pazos Y, et al. Central obestatin administration does not modify either spontaneous or ghrelin-induced food intake in rats. J Endocrinol Invest 2006; 29: RC13-5
90. Gourcerol G, Million M, Adelson DW, et al. Lack of interaction between peripheral injection of CCK and obestatin in the regulation of gastric satiety signalling in rodents. Peptides 2006; 27: 2811-9
91. Samson WK, White MM, Price C, et al. Obestatin acts in brain to inhibit thirst. Am J Physiol Regul Integr Comp Physiol 2007; 292: R637-43
92. Peyron C, Tighe DK, van den Pol AN, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015
93. Date Y, Ueta Y, Ymashita H, et al. Orexins, orexigenic hypothalamic peptides, interact with autonomic, neuroendocrine and neuroregulatory systems. Proc Natl Acad Sci U S A 1999; 96: 748-53
94. Mondal MS, Nakazato M, Date Y, et al. Widespread distribution of orexin in rat brain and its regulation upon fasting. Biochem Biophys Res Commun 1999; 256: 495-9
95. Marcus JN, Aschkenasi CJ, Lee CE, et al. Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol 2001; 435: 6-25
96. Triveldi P, Yu H, MacNeil DJ, et al. Distribution of orexin receptor mRNA in the rat brain. FEBS Lett 1998; 438: 71-5
97. Yamamoto Y, Ueta Y, Date Y, et al. Down regulation of the prepro-orexin gene expression in genetically obese mice. Mol Brain Res 1999; 65: 14-22
98. Cai XJ, Widdowson PS, Harrold J, et al. Hypothalamic orexin expression: modulation by blood glucose and feeding. Diabetes 1999; 48: 2132-7
99. Dube MG, Kalra SP, Kalra PS, et al. Food intake elicited by central administration of orexins/hypocretins: identification of hypothalamic sites of action. Brain Res 1999; 842: 473-7
100. Yamanaka A, Sakurai T, Katsumoto T, et al. Chronic intracerebroventricular administration of orexin-A to rats increases food intake in daytime, but has no effect on body weight. Brain Res 1999; 849: 248-52
101. Thorpe AJ, Mullett MA, Wang C, et al. Peptides that regulate food intake: regional, metabolic and circadian specificity of lateral hypothalamic orexin A feeding stimulation. Am J Physiol Regul Integr Comp Physiol 2003; 284: R1409-17
102. Haynes AC, Jackson B, Overend P, et al. Effects of single and chronic intracerebroventricular administration of the orexins on feeding in the rat. Peptides 1999; 20: 1099-105
103. Lubkin M, Stricker-Krongrad A. Independent feeding and metabolic actions of orexins in mice. Biochem Biophys Res Comm 1998; 253: 241-5
104. Wang J, Osaka T, Inoue S. Energy expenditure by intracerebroventricular administration of orexin to anaesthetized rats. Neurosci Lett 2001; 315: 49-52
105. Haynes AC, Jackson B, Chapman H, et al. A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept 2000; 96: 45-51
106. Haynes AC, Chapman H, Taylor C, et al. Anorectic, thermogenic and anti-obesity activity of a selective orexin-1 receptor antagonist in ob/ob mice. Regul Pept 2002; 104: 153-9
107. Lin L, Faraco J, Li R, et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999; 98: 365-76
108. O'Dowd BF, Scheideler MA, Nguyen T, et al. The cloning and chromosomal mapping of two novel human opioid- and somatostatin-like receptor genes, GPR7 and GPR8, expressed in distinct areas of the brain. Genomics 1995; 28: 84-91
109. Tanaka H, Yoshida T, Miyamoto N, et al. Characterization of a family of endogenous neuropeptide ligands for the G-protein coupled receptors GPR7 and GPR8. Proc Natl Acad Sci U S A 2003; 100: 6251-6
110. Lee DK, Nguyen T, Porter CA, et al. Two related G protein-coupled receptors: the distribution of GPR7 in rat brain and the absence of GPR8 in rodents. Mol Brain Res 1999; 71: 96-103
111. Singh G, Maguire JJ, Kuc RE, et al. Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [I125]-NPW radioligand binding and immunocytochemistry. Brain Res 2004; 1017: 222-6
112. Dun SL, Brailoiu C, Yang J, et al. Neuropeptide W-immunoreactivity in the hypothalamus and pituitary of the rat. Neurosci Lett 2003; 349: 71-4
113. Levine AS, Winsky-Sommerer R, Huitrin-Resendiz S, et al. Injection of neuropeptide W into paraventricular nucleus of hypothalamus increases food intake. Am J Physiol Regul Integr Comp Physiol 2005; 288: R1727-32
114. Mondal MS, Yamaguchi H, Date Y, et al. A role for neuropeptide W in the regulation of feeding behaviour. Endocrinology 2003; 144: 4729-33
115. Ishii M, Fei H, Friedman JM. Targeted disruption of GPR7, the endogenous receptor for neuropeptides B and W, leads to metabolic defects and adult-onset obesity. Proc Natl Acad Sci U S A 2003; 100: 10540-5